Long-Term Survival in the ALEX Trial: A Milestone in Improving the Prognosis of Patients with ALK-Positive Non-Small Cell Lung Cancer

Ann Oncol. 2025 Oct 17:S0923-7534(25)04933-6. doi: 10.1016/j.annonc.2025.10.001. Online ahead of print.

Authors

K-L Koster¹, M Früh²

Affiliations

¹ Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, HOCH Health Ostschweiz, St. Gallen, Switzerland.
² Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, HOCH Health Ostschweiz, St. Gallen, Switzerland; Department of Medical Oncology, University of Bern, Bern, Switzerland. Electronic address: Martin.Frueh@h-och.ch.

PMID: 41109818
DOI: 10.1016/j.annonc.2025.10.001

No abstract available

Publication types

Editorial